Filing Flows › Xtant Medical Holdings (XTNT) › R&D spending
Xtant Medical Holdings (XTNT) R&D spending by quarter
Xtant Medical Holdings' R&D spending was $695K in Q2 2026 (second quarter 2026), +60% from Q1 2026. Over the last 7 quarters it ranged from $435K (Q1 2026) to $695K (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $695K | +60% | +23% |
| Q1 2026 | $435K | -5% | -2% |
| Q4 2025 | $459K | -28% | -12% |
| Q3 2025 | $634K | +12% | — |
| Q2 2025 | $566K | +28% | — |
| Q1 2025 | $443K | -15% | — |
| Q4 2024 | $522K | — | — |
Q2 2026 at a glance
Xtant Medical Holdings, Q2 2026: revenue $23.0M (-35% year over year), operating margin -39.8%, net loss $9.4M, operating cash flow −$7.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Xtant Medical Holdings' R&D spending?
Xtant Medical Holdings' R&D spending was $695K in Q2 2026 (second quarter 2026), +60% from Q1 2026.
How has Xtant Medical Holdings' R&D spending changed?
Over the last 7 quarters it ranged from $435K (Q1 2026) to $695K (Q2 2026).
Q2 2026 results → · How Xtant Medical Holdings makes money →